小檗碱对于肥胖人群治疗疗效的Meta分析
The Efficacy of Berberine in the Treatment of Obese People: A Meta-Analysis
DOI: 10.12677/acm.2024.1482250, PDF,   
作者: 杨 娣, 袁小青：河北医科大学研究生学院，河北 石家庄；张力双*：石家庄市人民医院内分泌科，河北 石家庄
关键词: 小檗碱；肥胖；随机对照试验；Meta分析；Berberine； Obese； Randomized Controlled Trials； Meta-Analysis
摘要: 目的：系统评价小檗碱对于肥胖人群治疗的疗效。方法：采用计算机检索CNKI、CBM、WangFang、VIP、PubMed、Embase、Cochrane Library数据库，查找有关小檗碱对于肥胖人群治疗的随机对照试验研究，检索时间为建库至2023年12月，应用Stata 15.1软件对纳入的研究进行Meta分析。结果：最终有8项随机对照试验被纳入。Meta分析结果显示，与对照组相比，小檗碱组可有效降低受试者BMI值[SMD = −0.67, 95% CI (−0.91, −0.44), P < 0.001]；降低总胆固醇[SMD = −0.42, 95% CI (−0.52, −0.32), P < 0.001]；降低低密度脂蛋白[SMD = −0.42, 95% CI (−0.52, −0.32), P < 0.001]；升高高密度脂蛋白[SMD = 0.72, 95% CI (0.61, 0.82), P < 0.001]；降低甘油三酯[SMD = −0.38, 95% CI (−0.48, −0.28), P < 0.001]。结论：当前证据表明小檗碱对于肥胖人群治疗疗效较好，能够有效地降低BMI和血脂水平。
Abstract: Objective: To review the efficacy of berberine in the treatment of obese people. Method: CNKI, CBM, WangFang Date, VIP databases, PubMed, Embase and Cochrane Library were searched in computer to find randomized controlled trials of berberine in obese people from library establishment to December 2023. Stata 15.1 software was used to conduct a meta-analysis of the included studies. Result: Eight randomized controlled trials were included. The results of meta-analysis found that compared with control group, berberine group was more effective in reducing the BMI of the subject [SMD = −0.67, 95% CI (−0.91, −0.44), P < 0.001]; reducing TC [SMD = −0.42, 95% CI (−0.52, −0.32), P < 0.001]; reducing LDL [SMD = −0.42, 95% CI (−0.52, −0.32), P < 0.001]; increasing HDL [SMD = 0.72, 95% CI (0.61, 0.82), P < 0.001]; reducing TG [SMD = −0.38, 95% CI (−0.48, −0.28), P < 0.001]. Conclusion: Current evidence suggests that berberine is more effective in the treatment of obese people, effectively reducing BMI and lipid levels.
文章引用：杨娣, 张力双, 袁小青. 小檗碱对于肥胖人群治疗疗效的Meta分析[J]. 临床医学进展, 2024, 14(8): 550-559. https://doi.org/10.12677/acm.2024.1482250

参考文献

[1] 中国营养学会肥胖防控分会, 中国营养学会临床营养分会, 中华预防医学会行为健康分会, 等. 中国居民肥胖防治专家共识[J]. 中华流行病学杂志, 2022, 43(5): 609-626.
[2] Wang, Y., Zhao, L., Gao, L., Pan, A. and Xue, H. (2021) Health Policy and Public Health Implications of Obesity in China. The Lancet Diabetes & Endocrinology, 9, 446-461. [Google Scholar] [CrossRef] [PubMed]
[3] Pan, X., Wang, L. and Pan, A. (2021) Epidemiology and Determinants of Obesity in China. The Lancet Diabetes & Endocrinology, 9, 373-392. [Google Scholar] [CrossRef] [PubMed]
[4] Wang, Y., Xue, H., Sun, M., Zhu, X., Zhao, L. and Yang, Y. (2019) Prevention and Control of Obesity in China. The Lancet Global Health, 7, e1166-e1167. [Google Scholar] [CrossRef] [PubMed]
[5] Habtemariam, S. (2020) Berberine Pharmacology and the Gut Microbiota: A Hidden Therapeutic Link. Pharmacological Research, 155, Article 104722. [Google Scholar] [CrossRef] [PubMed]
[6] Zhang, L., Wu, X., Yang, R., Chen, F., Liao, Y., Zhu, Z., et al. (2021) Effects of Berberine on the Gastrointestinal Microbiota. Frontiers in Cellular and Infection Microbiology, 10, Article 588517. [Google Scholar] [CrossRef] [PubMed]
[7] Higgins, J.P. (2011) Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration.
[8] 窦君清, 邢渊, 张蓉芳. 小檗碱对肥胖患者血清C反应蛋白的影响[J]. 实用药物与临床, 2012, 15(3): 147-148.
[9] 刘庆丰, 李中东, 施孝金, 等. 三黄口服液治疗代谢综合征的疗效观察[J]. 中药药理与临床, 2012, 28(4): 104-106.
[10] Di Bisceglie, A., Watts, G., Linberg, B., Yu, L., Yu, M., Lavin, P., et al. (2020) A Randomized, Double Blind, Placebo-Controlled Trial of Htd1801 (berberine Ursodeoxycholate, Budc) in Patients with Hypercholesterolemia: Implications for Its Use in Non-Alcoholic Steatohepatitis (nash). Journal of Hepatology, 73, S440-S441. [Google Scholar] [CrossRef] 
[11] Affuso, F. (2012) A Nutraceutical Combination Improves Insulin Sensitivity in Patients with Metabolic Syndrome. World Journal of Cardiology, 4, 77-83. [Google Scholar] [CrossRef] [PubMed]
[12] Derosa, G., D’Angelo, A., Vanelli, A. and Maffioli, P. (2020) An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia Diabetes. Metabolic Syndrome and Obesity: Targets and Therapy, 13, 653-661. [Google Scholar] [CrossRef] [PubMed]
[13] Galletti, F., Fazio, V., Gentile, M., Schillaci, G., Pucci, G., Battista, F., et al. (2019) Efficacy of a Nutraceutical Combination on Lipid Metabolism in Patients with Metabolic Syndrome: A Multicenter, Double Blind, Randomized, Placebo Controlled Trial. Lipids in Health and Disease, 18, Article No. 66. [Google Scholar] [CrossRef] [PubMed]
[14] Manzato, E. and Benvenuti C. (2014) Controlled Clinical Study on the Effect of a Patented Combination of Berberine, Red Yeast Rice and Orthosiphon on Lipids and Borderline High Blood Pressure versus Diet Alone in Metabolic Syndrome. European Journal of Preventive Cardiology, 21, 116.
[15] Pérez-Rubio, K.G., González-Ortiz, M., Martínez-Abundis, E., Robles-Cervantes, J.A. and Espinel-Bermúdez, M.C. (2013) Effect of Berberine Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion. Metabolic Syndrome and Related Disorders, 11, 366-369. [Google Scholar] [CrossRef] [PubMed]
[16] Yang, Y., Liu, F., Lu, R. and Jia, J. (2019) Berberine Inhibits Adipogenesis in Porcine Adipocytes via Amp-Activated Protein Kinase-Dependent and Independent Mechanisms. Lipids, 54, 667-678. [Google Scholar] [CrossRef] [PubMed]
[17] Zhang, Z., Zhang, H., Li, B., Meng, X., Wang, J., Zhang, Y., et al. (2014) Berberine Activates Thermogenesis in White and Brown Adipose Tissue. Nature Communications, 5, Article No. 5493. [Google Scholar] [CrossRef] [PubMed]
[18] Li, Z., Jiang, J. and Kong, W. (2014) Berberine Up-Regulates Hepatic Low-Density Lipoprotein Receptor through Ras-Independent but Amp-Activated Protein Kinase-Dependent Raf-1 Activation. Biological and Pharmaceutical Bulletin, 37, 1766-1775. [Google Scholar] [CrossRef] [PubMed]
[19] Kim, W.S., Lee, Y.S., Cha, S.H., Jeong, H.W., Choe, S.S., Lee, M., et al. (2009) Berberine Improves Lipid Dysregulation in Obesity by Controlling Central and Peripheral AMPK Activity. American Journal of Physiology-Endocrinology and Metabolism, 296, E812-E819. [Google Scholar] [CrossRef] [PubMed]
[20] Cha, S., Rodgers, J.T., Puigserver, P., Chohnan, S. and Lane, M.D. (2006) Hypothalamic Malonyl-Coa Triggers Mitochondrial Biogenesis and Oxidative Gene Expression in Skeletal Muscle: Role of Pgc-1α. Proceedings of the National Academy of Sciences, 103, 15410-15415.
[21] Cha, S.H., Hu, Z., Chohnan, S. and Lane, M.D. (2005) Inhibition of Hypothalamic Fatty Acid Synthase Triggers Rapid Activation of Fatty Acid Oxidation in Skeletal Muscle. Proceedings of the National Academy of Sciences, 102, 14557-14562. [Google Scholar] [CrossRef] [PubMed]
[22] Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., et al. (2004) Berberine Is a Novel Cholesterol-Lowering Drug Working through a Unique Mechanism Distinct from Statins. Nature Medicine, 10, 1344-1351. [Google Scholar] [CrossRef] [PubMed]
[23] Martínez-Abundis, E., Mendez-del Villar, M., Pérez-Rubio, K.G., Zuñiga, L.Y., Cortez-Navarrete, M., Ramírez-Rodriguez, A., et al. (2016) Novel Nutraceutic Therapies for the Treatment of Metabolic Syndrome. World Journal of Diabetes, 7, 142-152. [Google Scholar] [CrossRef] [PubMed]
[24] Wang, Y., Tong, Q., Shou, J., Zhao, Z., Li, X., Zhang, X., et al. (2017) Gut Microbiota-Mediated Personalized Treatment of Hyperlipidemia Using Berberine. Theranostics, 7, 2443-2451. [Google Scholar] [CrossRef] [PubMed]
[25] Cao, Y., Pan, Q., Cai, W., et al. (2016) Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice. Archives of Iranian Medicine, 19, 197-203.
[26] Ley, R.E., Bäckhed, F., Turnbaugh, P., Lozupone, C.A., Knight, R.D. and Gordon, J.I. (2005) Obesity Alters Gut Microbial Ecology. Proceedings of the National Academy of Sciences, 102, 11070-11075. [Google Scholar] [CrossRef] [PubMed]

为你推荐